Stockscreener 앱 받기
2.90
5.07%
0.14
시간 외 거래:
2.91
0.01
+0.34%
전일 마감가:
$2.76
열려 있는:
$2.89
하루 거래량:
1.44M
Relative Volume:
0.54
시가총액:
$327.83M
수익:
$14.79M
순이익/손실:
$-102.44M
주가수익비율:
-0.9539
EPS:
-3.04
순현금흐름:
$-91.73M
1주 성능:
-31.44%
1개월 성능:
+7.41%
6개월 성능:
-47.37%
1년 성능:
-72.09%
1일 변동 폭
$2.76
$3.005
1주일 범위
$2.52
$4.189
52주 변동 폭
$2.45
$10.68
솔리드 바이오 Stock (SLDB) Company Profile
명칭
Solid Biosciences Inc
전화
617-337-4680
주소
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
SLDB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLDB
Solid Biosciences Inc
|
2.90 | 327.83M | 14.79M | -102.44M | -91.73M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.37 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.63 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
560.90 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.19 | 35.67B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
233.25 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
솔리드 바이오 Stock (SLDB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-08 | 개시 | Truist | Buy |
| 2024-12-13 | 개시 | Wedbush | Outperform |
| 2024-12-10 | 개시 | JMP Securities | Mkt Outperform |
| 2024-07-15 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-06-24 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-05-31 | 재개 | Piper Sandler | Overweight |
| 2024-03-28 | 개시 | William Blair | Outperform |
| 2024-03-15 | 개시 | Citigroup | Buy |
| 2024-03-14 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-12-08 | 개시 | H.C. Wainwright | Buy |
| 2021-07-12 | 개시 | Piper Sandler | Neutral |
| 2021-05-27 | 개시 | Jefferies | Buy |
| 2021-03-16 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-09 | 개시 | Barclays | Overweight |
| 2021-01-08 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2020-07-28 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-05-07 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-10-11 | 개시 | Evercore ISI | Outperform |
| 2019-08-29 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2019-08-19 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-08-16 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2019-05-14 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2019-05-14 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-02-08 | 업그레이드 | Citigroup | Sell → Neutral |
| 2019-02-08 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2018-11-06 | 개시 | Citigroup | Sell |
| 2018-09-06 | 개시 | Credit Suisse | Neutral |
모두보기
솔리드 바이오 주식(SLDB)의 최신 뉴스
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Solid Biosciences Expands Team: 81,000 RSUs Awarded to 7 Strategic New Hires - Stock Titan
Solid Biosciences to Participate at The Citizens Life Sciences Conference - The Manila Times
Exclusive: Solid Biosciences CEO Ready to Reveal Latest Company Vision at Major Life Sciences Event - Stock Titan
Solid Biosciences to Present at the American Society of Gene and Cell Therapy's 28th Annual Meeting - The Manila Times
Solid Biosciences to Present Phase 1/2 Trial Data for SGT-003 Gene Therapy at ASGCT 2025 Annual Meeting - Nasdaq
Solid Biosciences to Present at the American Society of Gene and Cell Therapy’s 28th Annual Meeting - GlobeNewswire
New Duchenne Treatment Breakthrough: Solid Bio Unveils Critical Gene Therapy Trial Results at Major Conference - Stock Titan
Montai Therapeutics Appoints Allison Bogosian, JD, as Chief People and Administrative Officer - Business Wire
Piper Sandler Remains a Buy on Solid Biosciences (SLDB) - The Globe and Mail
Certain Restricted Stock Units of Solid Biosciences Inc. are subject to a Lock-Up Agreement Ending on 20-APR-2025. - marketscreener.com
Certain Common Stock of Solid Biosciences Inc. are subject to a Lock-Up Agreement Ending on 20-APR-2025. - marketscreener.com
Solid Biosciences stock hits 52-week low at $2.47 By Investing.com - Investing.com South Africa
Solid Biosciences stock hits 52-week low at $2.47 - Investing.com Australia
Can Solid Biosciences Challenge Sarepta in the DMD Market? - MSN
Solid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy Space - Seeking Alpha
Solid Biosciences stock hits 52-week low at $2.88 - Investing.com Australia
Solid Biosciences stock hits 52-week low at $2.88 By Investing.com - Investing.com South Africa
Solid Biosciences to Participate at Upcoming Investor Conferences - GlobeNewswire
Exclusive Access: Solid Biosciences Leadership Team Headlines Two Major Healthcare Conferences - Stock Titan
Solid Biosciences reports inducement grants under Nasdaq listing rule - TipRanks
Solid Biosciences Expands Team with 43,374 RSU Grants in Strategic Hiring Move - Stock Titan
Sarepta safety update on Elevidys boosts Regenxbio, hurts Solid Bio - MSN
Truist Financial Keeps Their Buy Rating on Solid Biosciences (SLDB) - The Globe and Mail
Solid Biosciences Inc.'s (NASDAQ:SLDB) market cap dropped US$53m last week; Private equity firms bore the brunt - simplywall.st
Regenxbio stock up, Solid Bio down post Sarepta update (RGNX) - Seeking Alpha
Solid Biosciences Inc. (SLDB): Among Top Insider Purchases Last Month - Insider Monkey
Solid Biosciences director Kahn Clare buys $9,924 in stock - Investing.com India
Solid Biosciences director Kahn Clare buys $9,924 in stock By Investing.com - Investing.com Australia
Solid Biosciences’ SWOT analysis: gene therapy firm’s stock poised for growth - Investing.com Australia
Solid Biosciences’ SWOT analysis: gene therapy firm’s stock poised for growth By Investing.com - Investing.com South Africa
Solid Biosciences Inc. (NASDAQ:SLDB) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Solid Biosciences Inc. (NASDAQ:SLDB) Short Interest Update - Defense World
Q1 EPS Forecast for Solid Biosciences Boosted by Analyst - Defense World
Top 10 Insider Purchases Last Month - Insider Monkey
Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - GlobeNewswire
Solid Biosciences Inc. to Present Phase 1/2 INSPIRE DUCHENNE Trial Data on SGT-003 Gene Therapy for Duchenne Muscular Dystrophy at 2025 MDA Conference - Nasdaq
Breakthrough DMD Gene Therapy Results: Solid Bio Reveals INSPIRE Trial Data at Major Conference - StockTitan
Solid Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Solid Biosciences Inc. (NASDAQ:SLDB) Shares Acquired by Rhumbline Advisers - Defense World
솔리드 바이오 (SLDB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
솔리드 바이오 주식 (SLDB) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Bain Capital Life Sciences Inv | 10% Owner |
Feb 19 '25 |
Buy |
4.03 |
1,000,000 |
4,030,000 |
5,034,582 |
| PERCEPTIVE ADVISORS LLC | Director |
Feb 19 '25 |
Buy |
4.03 |
5,000,000 |
20,150,000 |
11,833,539 |
| Adage Capital Management, L.P. | 10% Owner |
Feb 18 '25 |
Buy |
7.56 |
252,545 |
1,909,240 |
4,248,084 |
| Hanrahan Jessie | Chief Regulatory Officer |
Feb 14 '25 |
Sale |
3.96 |
3,079 |
12,193 |
19,281 |
| Brooks Gabriel | Chief Medical Officer |
Feb 14 '25 |
Sale |
3.96 |
3,256 |
12,894 |
22,812 |
| Tan Kevin | CFO & Treasurer |
Feb 14 '25 |
Sale |
3.96 |
3,164 |
12,529 |
32,250 |
| Howton David T | Chief Operating Officer |
Feb 14 '25 |
Sale |
3.96 |
5,561 |
22,022 |
24,789 |
| Herzich Paul | Chief Technology Officer |
Feb 14 '25 |
Sale |
3.96 |
2,688 |
10,644 |
18,388 |
| Cumbo Alexander | President and CEO |
Feb 14 '25 |
Sale |
3.96 |
11,365 |
45,005 |
60,717 |
| Ganot Ilan | Director |
Feb 14 '25 |
Sale |
3.96 |
1,711 |
6,776 |
14,839 |
4.10%
자본화:
|
볼륨(24시간):